Galderma's nemolizumab shows long-term efficacy and durability in Prurigo Nodularis and Atopic Dermatitis.

Galderma presents new data at AAD 2024, showcasing nemolizumab's long-term efficacy in Prurigo Nodularis and durability in Atopic Dermatitis. In Prurigo Nodularis, one-year data from the OLYMPIA LTE study reveals 80% improvement in itch and 60% clear/almost-clear skin for nemolizumab-treated patients. In Atopic Dermatitis, ARCADIA clinical trial results indicate that skin and itch responses are maintained through week 48, even with reduced dosing from every 4 weeks to every 8 weeks.